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Open acca b s t r a c t
Myelodysplastic syndromes are heterogeneous myeloid neoplasms ranging from indolent conditions
with a near-normal life expectancy to forms approaching acute myeloid leukemia. Here we report a 51-
year-old woman with depression and severe obesity who was diagnosed with an International
Prognostic Scoring System low-risk myelodysplastic syndrome, presenting mainly with thrombocyto-
penia, treated with escalating dose of valproic acid as a single agent. After two years of treatment her
platelet count is almost normal and the tolerance to therapy is good. It is already known that valproic acid
could be used in high-risk myelodysplastic syndromes and acute myeloid leukemia, mainly in association
with other drugs, but its role in low-risk myelodysplastic syndrome is not well established yet.
& 2013 Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal stem cell disorders associated with worsening cytopenias
and leading to reduced survival and a compromised quality of
life.1,2 Treatment for MDS patients with low-risk disease generally
requires the management of the patient's symptomatic anemia
with its attendant fatigue.3 Patients with severe thrombocytopenia
(rarely the only cytopenia) also require supportive management.
The prevalence of thrombocytopenia o100109/l in MDS ranges
from 33% to 76%.4–6 Severe thrombocytopenia is generally mana-
ged with platelet (PLT) transfusion support (at levels ≤10109 or
≤20109/l for clinical bleeding). Peri-operative platelet transfu-
sion support is often needed for patients with even higher PLT
counts due to their frequent thrombocytopathy.
There is no consensus about how to treat isolated thrombocy-
topenia in MDS patients and several drugs are under investigation.
Romiplostim is an Fc-fusion protein that augments thrombo-
poiesis by binding to and activating the thrombopoietin receptor.7
It is approved for the treatment of thrombocytopenia in patients
with chronic immune thrombocytopenic purpura who have had
an insufﬁcient response to corticosteroids, immunoglobulins, or
splenectomy. Romiplostim is under investigation for thrombocy-
topenia in patients with International Prognostic Scoring System
(IPSS)8 low-risk or intermediate 1-risk MDS who are not currentlynca, 71, 60126 Ancona, Italy.
i.marche.it,
ess under CC BY-NC-ND license.receiving disease-modifying treatment and in patients who have
MDS with grade 3 or 4 treatment-related thrombocytopenia. Few
phase II clinical trials have demonstrated the efﬁcacy of romiplos-
tim for increasing PLT levels and decreasing thrombocytopenic
adverse events either alone or in combination with hypomethylat-
ing agents.9–11
The novel nonpeptide thrombopoietin receptor agonist eltrom-
bopag was approved also for treatment of patients with chronic
idiopathic thrombocytopenic purpura (ITP) in the United States
and in Europe. Eltrombopag has been shown to effectively elevate
PLT numbers and reduce thrombocytopenia-related complications
in patients with chronic ITP or hepatitis C.12,13 This drug is now
under investigation for thrombocytopenia in low-risk MDS.14,15
Valproic acid is another drug which has shown an antileukemic
activity mainly when used in association and in high-risk MDS and
AML.16–18
Its current use in low-risk MDS is neither clear nor well
established (Table 1 shows an overview of the published studies).2. Case study
A 51-years-old woman came to our attention on February 2010
for decreased PLT count (PLT 39109/L) and an increase in the
mean corpuscular volume (MCV) without anemia (Hb 12.6 g/dL,
MCV 104.3 fL) or leukopenia (WBC 5.06109/L, neutrophils
3.50109/L) which were discovered by chance after a routine
check of the complete blood cell (CBC) count. Anti-PLT I and D
antibodies were absent. Physical examination did not show
splenomegaly, showed a severe obesity (body mass index¼33),
Table 1
Overview of the studies on the use of VA in MDS.
Author Cohort Treatment schedule Response rate
Siitonen et al.
MDS/CMML
VA dose escalation in 2 weeks-[VA] 500–700 mcmol/L+13-cis-retinoid acid 10 mg
twice a day+Vitamin D3 1 mcg once a day
16% HI
Haematologica 2007
Ryningen et al.
AML
VA dose escalation i.v. for 5 day (then oral therapy until the appearance of side effects),
after 5 days given orally+ATRA 22.5 mg twice a day for 14 days every 3 months
+Theoplylline-[theophylline] 50–100 mcM
41% HI
Leukemia Research 2008
Voso et al.
MDS/AML
VA dose escalation-[VA]450 mcg/mL+5-aza 75 mg/m2 daily for 7 days (repeated
once every 28 days)
30% (CR+PR)
Cancer Research 2009
Cimino et al.
AML
VA dose escalation-[VA] 50–110 mcg/mL+ATRA 22.5 mg twice a day (since VA is in
range or since day 14 from VA start)
25% HI
Cancer Research 2006
Kuendgen et al.
MDS/AML
VA dose escalation-[VA] 50–100 mcg/mL+ATRA 40 mg twice a day for 7 days every
other week
24% HI
Blood 2004
Pilatrino et al.
MDS/AML
VA dose escalation-[VA] 45–100 mcg/mL+ATRA 45 mg once a day (since VA is in
range)
“Clinical beneﬁt” 30%
Cancer 2005
Kuendgen et al.
MDS/AML
VA dose escalation-[VA] 80–110 mcg/mL+5-aza 100 mg/m2 daily for 5 days (repeated
once every 28 days)
37% (CR+PR)
Clinical Epigenetics 2012
MDS: myelodysplastic syndrome, AML: acute myeloid leukemia, ATRA: all trans retinoic acid, 5-aza: 5-azacitidine, HI: hematological improvement, CR: complete remission,
PR: partial remission, i.v.: intra vein.
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Fig. 1. PLT count trend during the treatment with Valproic Acid (according to VA
serum concentration).
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with risperidone. Since this was suggestive for a MDS, on 25th of
February 2010 a bone marrow (BM) evaluation was performed; the
BM aspirate was not evaluable, while the trephine showed a
cellularity of 30%, an erythroid slow maturation with an increase
of haemosiderin, small and medium size of the megakaryocytes
precursors and no abnormality or maturation defects of the
myeloid progenitors, myeloid blasts were less than 5%, no sign of
bone marrow ﬁbrosis. Cytogenetic was normal. The patient was
eventually diagnosed with a IPSS low and WPSS very low risk
MDS; considering her comorbidities, and the absence of a sibling
donor she was considered noneligible for allogeneic stem cell
transplantation; the patient also refused to be enrolled in a clinical
trial for the use of eltrombopag in low risk MDS. As the patient
never reported any bleeding, the ﬁnal decision was to adopt a
watch and wait strategy and the thrombocytopenia remained
stable until May 2010 (40109/L). On June 2010 PLT count started
to decrease and we decided, after having properly informed the
patient, to start valproic acid starting 200 mg per day with a
weekly assessment of serum valproic acid concentration (normal
range in our laboratory: 50–100 mcg/L); the decision to start from
such a low valproic acid dosage was made based on our limited
experience with this drug. There was a progressive increase in
drug dosage up to 1200 mg per day on November 2010 (with this
dosage valproic acid serum concentration permanently raised up
to 70 mcg/L). The PLT count stayed stable around 20109/L untilDecember 2010. Since January 2011 the serum level of valproic
acid moved to the upper normal limit (100 mcg/L) and PLT
increased up to 30109/L in January and up to 40109/L in April,
50109/L in June, 60109/L in September when she had to
decrease the dosage down to 1000 mg per day due to tremor
and sleepiness. In November PLT count was 72109/L. She is
currently under treatment with valproic acid 1000 mg per day and
her PLT count is constantly higher than 90109/L (Fig. 1 shows the
trend of PLT count according to VA serum concentration).3. Discussion
Here we report a case of a low-risk MDS with just one
cytopenia successfully treated with valproic acid (12 months of
hematological response). According to National Comprehensive
Cancer Network (NCCN) guidelines, the treatment for clinically
relevant neutropenia or thrombocytopenia ranges from hypo-
methylating agents (not approved in Italy for this setting of
patients) to allogeneic stem cell transplantation or immunosup-
pressive treatment for nonresponders to hypomethylating drugs.
Still the best choice is to include them in clinical trials.
Valproic acid is a potent inhibitor of histone deacetylases
(HDAC). It can modify the structure of chromatin allowing recruit-
ment of transcription factors to restore epigenetically suppressed
genes.19 Valproic acid has been shown to possess antiproliferative
activity and to overcome the differentiation block in leukemia
blast cells.20,21 Valproic acid concentrations consistent with nor-
mal clinical dosage are believed to achieve the inhibition of
HDAC.20,22
In 2004 Kuendgen et al. observed a response, according to
international working group (IWG) criteria23, in 8 patients (both
high-risk MDS and AML) (44%) on Valproic acid monotherapy,
including 1 partial remission and median response duration was
4 months (range 3–9 months).24 Later on, the same group
conﬁrmed their results in the same setting of patients and found
that all trans retinoic acid (ATRA) could add some beneﬁts in
valproic acid nonresponders.25 Almost the same observations
were made by an Italian group in 2005; they observed a clinical
beneﬁt in 30% of their patients (high-risk MDS and AML) treated
with a combination of both valproic acid and ATRA.26 The associa-
tion HDAC inhibitors and hypomethylating agents was also used in
IPSS high risk MDS and in AML patients and 30% of patients obtained
a remission (complete and partial) suggesting, according to the
authors, that valproic acid could enhance azacitidine efﬁcacy.18 The
A. Poloni et al. / Leukemia Research Reports 2 (2013) 44–4646same drug association was used by a German group and conﬁrmed
the results shown by Voso et al..27
In conclusion, we have reported a case of a low-risk MDS
patient who was successfully treated with escalating doses of
valproic acid and showed a good response; this therapy was safe
(no grade 3 or 4 toxicity), effective, feasible, and inexpensive.
Clinical randomised trials are needed to conﬁrm the antileukemic
activity of this drug (in combination with others, e.g. hypomethy-
lating agents) in high-risk MDS and AML and to extend its use to
low-risk disease. The identiﬁcation of cytogenetic and molecular
features able to predict the response to valproic acid would be
useful as well.
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